Sensimed CEO Discloses Financing, Next Steps
Sensimed CEO David Bailey recounts his maiden presentation to OIS and shares information on the company’s recent financing, including a commitment from a new strategic investor. He also explains why ocular volume change could be a clinically relevant measurement for glaucoma.
Participant:
![David Bailey](https://ois.net/wp-content/uploads/2016/09/David-Bailey-500x500-website-2016.jpg)
Barry Cheskin
David Bailey has over 30 years of executive experience across major corporations and geographies in the Medical Device and Pharmaceutical industry including seven years as CEO of a USA public company.